DrugPatentWatch Database Preview
Email this page to a colleague» See Plans and Pricing
« Back to Dashboard
Merestinib is an investigational drug.
There have been 8 clinical trials for Merestinib. The most recent clinical trial was a Phase 1 trial, which was initiated on May 1st 2016.
The most common disease conditions in clinical trials are Neoplasm Metastasis, Neoplasms, and Urinary Bladder Neoplasms. The leading clinical trial sponsors are Eli Lilly and Company, University of Utah, and Jacqueline Garcia, MD.
There are five US patents protecting this investigational drug and fifty-four international patents.
Recent Clinical Trials for Merestinib
|Merestinib on Bone Metastases in Subjects With Breast Cancer||Eli Lilly and Company||Phase 1|
|Merestinib on Bone Metastases in Subjects With Breast Cancer||University of Utah||Phase 1|
|Combination Merestinib and LY2874455 for Patients With Relapsed or Refractory Acute Myeloid Leukemia||Eli Lilly and Company||Phase 1|
Top disease conditions for Merestinib
Top clinical trial sponsors for Merestinib
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Merestinib||Start Trial||Methods of treating a neuroendocrine tumor||SCRIPPS HEALTH (San Diego, CA)||Start Trial|
|Merestinib||Start Trial||Targeted therapeutics||MADRIGAL PHARMACEUTICALS, INC. (West Conshohocken, PA)||Start Trial|
|Merestinib||Start Trial||Amidophenoxyindazoles useful as inhibitors of c-Met||Eli Lilly and Company (Indianapolis, IN)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Merestinib||World Intellectual Property Organization (WIPO)||2019040497||2037-08-22||Start Trial|
|Merestinib||World Intellectual Property Organization (WIPO)||2015066053||2033-10-28||Start Trial|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|